Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 3/20 | 0.42 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.34 |
| ▸ | CHRNB4 known ✓ | P30926 | 4/20 | 0.33 |
| ▸ | CHRNA3 known ✓ | P32297 | 4/20 | 0.33 |
| ▸ | NOS3 | P29474 | 3/20 | 0.54 |
| ▸ | NOS2 | P35228 | 3/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.54 |
| ▸ | CCR1 | P32246 | 3/20 | 0.42 |
| ▸ | CCR8 | P51685 | 3/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7487 | 0.97 | — | — | |
| SCHEMBL29382337 | 0.97 | — | — | |
| SCHEMBL9784696 | 0.97 | NOS3 (0.56) | NOS3NOS2NOS1CCR1CCR5 | |
| Fluoride SCHEMBL3185683 | 0.94 | NOS3 (0.54) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL29735919 | 0.94 | NOS3 (0.54) | NOS3NOS2NOS1CCR1CCR5 | |
| Hydrogen Sulfide SCHEMBL5051770 | 0.94 | NOS3 (0.54) | NOS3NOS2NOS1CCR1CCR5 | |
| Iodide SCHEMBL11070567 | 0.94 | NOS3 (0.54) | NOS3NOS2NOS1CCR1CCR5 | |
| Bromide SCHEMBL10623431 | 0.94 | NOS3 (0.54) | NOS3NOS2NOS1CCR1CCR5 | |
| Acetonitrile SCHEMBL27689078 | 0.85 | NOS3 (0.46) | NOS3NOS2NOS1CCR1CCR5 | |
| Acetic Acid SCHEMBL11227068 | 0.84 | NOS3 (0.45) | NOS3NOS2NOS1CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189876-B2 | Methods for preparing sertraline hydrochloride polymorphs | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2007-03-13 | — | — | US | claimed |
| EP-1648854-A1 | METHODS FOR PREPARING SERTRALINE HYDROCHLORIDE POLYMORPHS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2006-04-26 | — | — | EP | claimed |
| US-20050032907-A1 | Methods for preparing sertraline hydrochloride polymorphs | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2005-02-10 | — | — | US | claimed |
| WO-2005012225-A1 | METHODS FOR PREPARING SERTRALINE HYDROCHLORIDE POLYMORPHS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2005-02-10 | — | — | WO | claimed |
| EP-1135382-A1 | METHOD OF PRODUCING PAROXETINE HYDROCHLORIDE | SMITHKLINE BEECHAM PLC (GB) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032593-A1 | METHOD OF PRODUCING PAROXETINE HYDROCHLORIDE | SMITHKLINE BEECHAM PLC (GB) | 2000-06-08 | — | — | WO | claimed |
| US-5629134-A | SOLVENT, ALKALI SOLUBLE RESIN, ACID GENERATOR, PYRIDINE SALT | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1997-05-13 | — | — | US | claimed |
| EP-0058591-B1 | EPIMERISATION OF TRANS CHRYSANTHEMIC ACIDS AND INTERMEDIATES OBTAINED THEREFROM | ROUSSEL-UCLAF (FR) | 1984-10-03 | — | — | EP | claimed |
| US-4447637-A | Epimerization of trans chrysanthemates | ROUSSEL UCLAF (FR) | 1984-05-08 | — | — | US | claimed |
| CN-120118077-A | Compound and application thereof | 润尔眼科药物（广州）有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-119371426-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119350320-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-118362466-A | Hematology systems and methods | 艾瑞思国际股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-113484200-B | Hematology systems and methods | 艾瑞思国际股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-0097805-A2 | Nucleoside phosphite compounds | UNIVERSITY PATENTS, INC. (US) | 1984-01-11 | — | — | EP | disclosed |
| EP-0035719-A2 | Process for producing modified inorganic polymers, their use in producing polynucleotides, and a reagent useful in these processes | UNIVERSITY PATENTS, INC. (US) | 1981-09-16 | — | — | EP | disclosed |
| US-4212763-A | Bis-triazinylaminostilbene compounds and their use as fluorescent brightening agents | CIBA-GEIGY CORPORATION (US) | 1980-07-15 | — | — | US | disclosed |
| US-4110442-A | CARDIOVASCULAR DISORDERS | J. URIACH & CIA S.A. (ES) | 1978-08-29 | — | — | US | disclosed |
| US-4096252-A | THERAPY AND PROPHYLAXIS | J. URIACH & CIA S.A. (ES) | 1978-06-20 | — | — | US | disclosed |
| US-3979369-A | DIENE POLYMER | MONSANTO COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032907-A1 | Methods for preparing sertraline hydrochloride polymorphs | HTR1A, HTR3A, HTR5A | CCR5 238/4885HDAC6 1580/4885ADRA2A 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.